KLOW blend: what one draw actually delivers
KPV added to the GLOW three. Four peptides, one ratio, one draw — here is what that draw contains of each.
KLOW is GLOW with KPV added: four peptides in one vial, and the same structural problem as any blend, one component worse. A frequently circulated ratio is 10 mg of KPV and 50 mg of GHK-Cu to 10 mg each of BPC-157 and TB-500, which is the reference below — but as with every blend on this site, there is no standard and your label is the only authority on your vial.
Four components in a fixed ratio means four dosing schedules collapsed into one. KPV's own described use is largely daily, and much of the interest in it is oral rather than injected — which a vial mixed for injection settles for you whether or not that is what you wanted.
volume to draw (ml) = dose wanted (mcg) ÷ that concentration
what the draw delivers of any other = that other (mg) × 1000 × volume ÷ water
units on a U-100 syringe = volume to draw (ml) × 100
Only the last line is specific to a blend, and it is the one people skip. A draw is a fraction of the vial, so it takes the same fraction of every component. Draw a fifth of the vial and you get a fifth of each thing in it.
The ratio problem, in numbers
Each row below anchors on one component at the low end of what the literature and community practice describe for that compound on its own, then shows what the same draw delivers of everything else in the vial. Computed for the reference vial — 10 mg KPV, 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 in 5 ml of bacteriostatic water — and the calculator above will redo it for yours.
| If you dose for | Draw | KPV | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|---|---|
| KPV at 250 mcg | 0.125 ml (12.5 u) | 250 mcg | 1.25 mg | 250 mcg | 250 mcg (13% of its own low end) |
| GHK-Cu at 1 mg | 0.1 ml (10 u) | 200 mcg | 1 mg | 200 mcg | 200 mcg (10% of its own low end) |
| BPC-157 at 200 mcg | 0.1 ml (10 u) | 200 mcg | 1 mg | 200 mcg | 200 mcg (10% of its own low end) |
| TB-500 at 2 mg | 1 ml (100 u) | 2 mg (8× its own low end) | 10 mg (10× its own low end) | 2 mg (10× its own low end) | 2 mg |
The amounts each row is anchored to, and where they come from:
- KPV — 250-500mcg, SubQ once daily (Systemic anti-inflammatory, from this site's compound reference)
- GHK-Cu — 1-2mg/day, Daily SubQ (SubQ systemic, from this site's compound reference)
- BPC-157 — 200-250mcg/day, Once daily SubQ near injury or orally (Starting, from this site's compound reference)
- TB-500 — 2-2.5mg twice weekly, SubQ or IM (Loading, from this site's compound reference)
Off-label or community practice None of these compounds is approved for human use, and the amounts above are what is described in the literature and in community practice rather than established doses. They are here as the yardstick the blend is being measured against, not as a recommendation. What matters on this page is the gap between the columns: it is a property of the vial's ratio, and no injection technique changes it.
Why this blend is put together the way it is
KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory effects through NF-κB inhibition, with much of the interest in gut conditions and much of the described use oral. It has an Orphan Drug Designation in progress for IBD and is not FDA approved. Putting it in an injectable blend is a route decision made by whoever mixed the vial, not by the evidence.
The other three behave as described on the GLOW page: GHK-Cu carries the copper consideration and usually the bulk of the mass, and BPC-157 and TB-500 disagree with each other about frequency before the other two are even counted. None of the four is approved for injected human use.
What is in the reference vial
- Components
- KPV · GHK-Cu · BPC-157 · TB-500
- Also called
- KLOW blend, KLOW peptide blend
- Reference vial
- 10 mg KPV + 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 in 5 ml bacteriostatic water
- Regulatory status
- KPV: Research compound — Orphan Drug Designation in progress for IBD. Not FDA approved.
GHK-Cu: Topical use is cosmetic/OTC. Systemic SubQ use is research only — no FDA approval.
BPC-157: Research compound — no FDA approval. Not for human use label.
TB-500: Research compound — no FDA approval. Not for human use label. - Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
Questions people actually ask
What is the difference between KLOW and GLOW?
KPV. GLOW circulates as GHK-Cu, BPC-157 and TB-500; KLOW is the same three with KPV added. Both names are community shorthand rather than formulations, so the ratios and even the component lists vary between sellers. Whichever you have, the arithmetic on this page is the same: one draw, every component, in the vial's ratio.
Should I take KPV orally instead?
A good deal of the published interest in KPV is in gut conditions, where oral dosing is the route being studied, and the app's own dosing reference lists both an oral and a subcutaneous entry for it. A blend vial mixed for injection has made that choice already. Whether the route you want matches the route your vial supports is worth settling before you mix it, and the question of which is appropriate for you belongs with a clinician.
Can I separate the components once the vial is mixed?
No. They are dissolved in the same water and go into the syringe together, in whatever ratio is in the vial. The only way to set each compound's amount independently is separate vials.
How do I know what is actually in my vial?
You do not, beyond what the label claims. None of these compounds is sold as an approved medicine, so nothing on the label has been verified by a regulator, and a blend adds a second unknown on top of the first: the ratio. The calculator is exact about the numbers you give it, and those numbers come from a label nobody checked. That is worth holding in mind before treating any output here as precise.
What about storage once it is reconstituted?
Mixed with bacteriostatic water, refrigerated at 2–8 °C and used within about 28 days is the rule the app applies to reconstituted peptides, and it applies to a blend as a whole rather than to each component. General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
Does the calculator know these are research compounds?
It does arithmetic, and nothing else. None of the compounds in this vial is approved for human use, and a calculator that tells you a draw is 40 units is not telling you the draw is a good idea. Anything you are considering injecting belongs in a conversation with a doctor who can see your whole picture.
A blend is one vial with several clocks running in it. The app keeps the vial, the concentration and every draw you take from it, so the split only has to be worked out once.
Save this draw to your logThis calculator does the arithmetic you typed and nothing else. It does not know what is actually in your vial, whether the label is accurate, or anything about you. Confirm the vial strength and the diluent volume on your own label before you draw, and take dosing decisions to a qualified provider.